Starting and Ironwood. exciting good additional Slide on Thanks, and for details to happy Tom, a was morning, transformative I'm quarter very everyone. provide on what X.
grew X% Tom continue As patients prescriptions care a choose was U.S. few mentioned growing and professionals driven This prescription year-over-year. increase strong in growth ago, to a in LINZESS by both XX% part in LINZESS new-to-brand and market. moments net a reinforcing the health demand year-over-year, sales
believe care with support a guideline for strong commercial momentum We class-leading satisfaction execution. formulary and professionals, the access, with treatment and high LINZESS both of of the combined health recommendations focused patients demand result is
approval, old in In LINZESS constipation, in a roughly addition, years indication treatment FDA to functional population. the ability Since this health granted help LINZESS been are been excited professionals positive, field million team far, care feedback to in for XX customers. United has of patient the six has our mentioned, patients the affects to ages prescribe which the by previously Thus X sales the new talented June years very States. as educating new was and
year in LINZESS response began July, as pediatric inform look XXXX. in updates in more providing to which geographies will sales promoting and we later help assess these potential from future to optimal the market also the will gain early this net insights and opportunity, we gastroenterologists investment We on In specific expansion based forward efforts. into promotional
Moving Slide on XX. on to our of acquisition VectivBio
conviction high enhanced Short extended and with portfolio part mechanism of based dosing to as are in We on as as the GI we program have action, apraglutide failure potency, apraglutide's compelling thrilled following Bowel convenience for reasons: have for of weekly date. unique designed to data well of the clinical the Syndrome intestinal its half-life our in
up In failure stoma continuity. addition, in both are intestinal is in patient evaluate of ongoing set syndrome III which to the Phase bowel study design with efficacy novel and short the populations, colon
best GI a in believe development, shareholders blockbuster As Ironwood medical execution, of by patients apraglutide and of expertise network maximize LINZESS. community, the in evidenced the commercial a leveraging we positioned clinical the for strong value our is success potential regulatory, existing with affairs company and as by to
significant operating leverage through a existing to potential in commercial drive We support XXXX, Ironwood's believe will commercial approved. if we capabilities launch
Ironwood patients long apraglutide apraglutide to extend based properties. achieve to the asset’s -- sales and catalyst on treated unique profile the XXXXs. the the in I bowel growth intestinal be term, through peak we in potential horizon significantly with the failure financial to to has believe an significant mentioned syndrome expand for the a This short earlier, providing with net has Ironwood's attractive create acquisition potential over billion As $X the
a on closing the with Additionally, I'd the VectivBio are brief provide to and where transaction like integration. we update
previously in successfully being for we cash, with the June, of we completed announced VectivBio $XX shares at share XX% of per purchase shares tender the of As to the ordinary offer outstanding end tendered. the
we the our and of with collaborating integrating business well. VectivBio began completion the which new and operations, Following Ironwood progressing colleagues tender is offer,
to taking merger We the necessary affect X% the of steps to VectivBio shares. remaining are acquire squeeze out Swiss under a law
be process of this the second XXXX. to expect during We half completed
process completed. filings will as We additional subsequent provide this and in steps are updates
for quarter. performance financial our on the details additional provide I'll Next,
As X%. of driven sales XX, were was growth U.S. shown of quarter by sales year-over-year. X% net XXXX, $XXX in the demand LINZESS of million an prescription on increase Slide growth Net second
Second due quarter favorable full erosion our price net to to guidance was net as price channel year compared mid-single-digit favorable previously mix. communicated
to Turning XXXX. Commercial the XX% profitability. to of compared second XX% quarter were in LINZESS XXXX of second in margins quarter brand the
we Ironwood million. the revenues quarter $XXX XXXX, the income In by primarily LINZESS quarter, April, acquisition. in two in We recorded the second of connection June, disclosed, by driven million XXXX. revenues. VectivBio of Ironwood of of second $XX with completed majority XX% revenues expense positions the million, as In to reduced commenced collaboration noncash. was our second headquarters-based approximately certain workforce of the Ironwood Moving personnel. our And restructurings Ironwood of tax $XXX were the quarter in elimination in U.S. previously of which
onetime billion benefits GAAP billion, generated $XX in-process and restructuring a in $X.X expenses $X.X $X charge comprised billion the million second and financing from adjustments, interest quarter, quarter. in adjusted other costs EBITDA and related income. net investment second and recorded and loss of interest the driven was VectivBio costs of Ironwood the expense $X.X of acquired $X.X research development approximately and acquisition. the to quarter, million a severance, the related in and second Ironwood was recorded in by primarily million of In loss employee
approximately revolving cash cash facility, funded million generated quarter operations from VectivBio. from flow cash cash on and cash our the proceeds In equivalents. $XXX we The of $XX quarter, through VectivBio the hand of with and and acquisition in in ended second million was credit
we horizon forward, continue flows, potential focus to XXXXs. while generating growth through to Moving and our cash on profits now maintain sustained our the the extend meaningful having
and commercial apraglutide generate ahead million $XXX of greater if year to successful cash expect approved of each a in We operating XXXX. launch, potential than flows
to to earnings to greater beginning accretive Additionally, by end return no of XXXX. expected to And of XXXX. is million share additional that business EBITDA the in activities, $XXX be assuming development we than adjusted VectivBio acquisition per expect
rapid of revolving of will EBITDA expect net delevering cash for the total approximately a flows credit commercial debt to EBITDA potential times anticipate end net three we for below agreement two to by We our total times XXXX. launch And LINZESS out a in of to XXXX. support apraglutide debt
manage our of value to our development portfolio maximize the structure through Moving forward, we'll paydown. capital continue investments LINZESS, to prioritize and progress debt
will additional maintain evaluate the to capital We for flexibility opportunities development.
on XXXX our Next, I'll Slide updated XX. review guidance
and we strong of expect performance -- guidance. our result million. Ironwood the between the of and year. continued $XXX of expect sales through $XXX an by U.S. Ironwood prescription half full X%, for strong We net the and million pricing first revenue increasing U.S. outlook a year, growth demand improved year and remainder sales of LINZESS LINZESS X% continued As now net revenue LINZESS now driven of between Accordingly, strong to we growth the are
are also We expect from approximately onetime to which guidance our includes million, the adjusted to reflect VectivBio. acquisition. $XXX a of now charge acquisition loss EBITDA revising approximately $X.X the of We billion
quarter second our year. first onetime cash EBITDA impact flows. the operating up, To of charge, of the half Excluding had representation approximate the an strong of wrap we adjusted and a is
position company. the our become strengthened to have health we believe leading care GI We
positioned and profits We GI are and and progressing LINZESS, portfolio innovative continued strengthening remain generating cash maximizing for sustained delivering we our well on growth, flow. focused and
several close all excited by the disorders. us, thanking and of want of for year. employees, their second shared our dedication development We're milestones half supporting of and about to progress I for to the we'll advocates our keep the therapies caregivers updated patients, GI continue and in on advancing key you ahead to
up Operator, line questions. now open the you may for
